228 related articles for article (PubMed ID: 30889997)
1. A patent update on cannabinoid receptor 1 antagonists (2015-2018).
Amato G; Khan NS; Maitra R
Expert Opin Ther Pat; 2019 Apr; 29(4):261-269. PubMed ID: 30889997
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.
Sharma MK; Murumkar PR; Barmade MA; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2015; 25(10):1093-116. PubMed ID: 26161824
[TBL] [Abstract][Full Text] [Related]
3. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
4.
Hirsch S; Tam J
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31096702
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
Nguyen T; Thomas BF; Zhang Y
Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Vemuri VK; Janero DR; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
[TBL] [Abstract][Full Text] [Related]
7. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
McLaughlin PJ
Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
Tam J
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
Janero DR; Makriyannis A
Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
[TBL] [Abstract][Full Text] [Related]
10. The Peripheral Cannabinoid Receptor Type 1 (CB
O'Sullivan SE; Yates AS; Porter RK
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684760
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
[TBL] [Abstract][Full Text] [Related]
12. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Lu D; Dopart R; Kendall DA
Cell Stress Chaperones; 2016 Jan; 21(1):1-7. PubMed ID: 26498013
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of targeting the peripheral endocannabinoid/CB
Tam J; Hinden L; Drori A; Udi S; Azar S; Baraghithy S
Eur J Intern Med; 2018 Mar; 49():23-29. PubMed ID: 29336868
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
15. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor antagonists and obesity.
Black SC
Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
[TBL] [Abstract][Full Text] [Related]
17. [Prospects for the Use of Cannabinoid Receptor Ligands for the Treatment of Metabolic Syndrome and Atherosclerosis: Analysis of Experimental and Clinical Data].
Maslov LN; Karpov RS
Vestn Ross Akad Med Nauk; 2017; 72(1):59-65. PubMed ID: 29308855
[TBL] [Abstract][Full Text] [Related]
18. Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.
Amato GS; Manke A; Harris DL; Wiethe RW; Vasukuttan V; Snyder RW; Lefever TW; Cortes R; Zhang Y; Wang S; Runyon SP; Maitra R
J Med Chem; 2018 May; 61(10):4370-4385. PubMed ID: 29688015
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.
Shi D; Zhan X; Yu X; Jia M; Zhang Y; Yao J; Hu X; Bao Z
Lipids Health Dis; 2014 Nov; 13():173. PubMed ID: 25406988
[TBL] [Abstract][Full Text] [Related]
20. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.
Wu YK; Yeh CF; Ly TW; Hung MS
Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
